ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2023 16:28:31 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

01 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

15 يونيو 2023 06:01:28 بحسب Nasdaq GlobeNewswire

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

06 يونيو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

25 مايو 2023 17:38:38 بحسب Nasdaq GlobeNewswire

Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations

23 مايو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

10 مايو 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting

26 أبريل 2023 10:00:11 بحسب Nasdaq GlobeNewswire

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023

17 أبريل 2023 09:00:01 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates

01 مارس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer

13 فبراير 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01 فبراير 2023 17:00:41 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

01 فبراير 2023 07:01:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يناير 2023 17:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ديسمبر 2022 17:00:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

09 نوفمبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

08 نوفمبر 2022 07:01:00 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2022 17:38:22 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

24 أكتوبر 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

17 أكتوبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire